15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 19 firms covering Zimmer Biomet Holdings Inc, 6 rate it Buy or better, 11 sit at Hold, and 2 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $86.00 to $112.00, so the covering firms are broadly aligned. The average target of $98.19 sits 3% above the current $95.74. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.88 next quarter toward $9.00 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS19 ratings
Moderate Buy
Strong Buy00%
Buy632%
Hold1158%
Sell211%
Strong Sell00%
Based on 19 analysts giving stock ratings to Zimmer Biomet Holdings Inc.
As of Jul, 6 of 19 firms rate ZBH a Buy (11 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
ZBH EPS & revenue forecast
EPS · NEXT QUARTER
$1.88
Range $1.85 – $1.93 · 22 analysts · -1% YoY
Next period, 22 analysts expect Zimmer Biomet Holdings Inc to earn $1.88 a share (range $1.85 – $1.93), versus $1.90 a year earlier. Full-year consensus is $8.48, growing to $9.00 the year after.
REVENUE · NEXT QUARTER
$2.0B
Range $2.0B – $2.1B · 22 analysts · +2% YoY
Revenue is expected to reach $2.0B (range $2.0B – $2.1B), +2.0% year-over-year. Full-year consensus is $8.5B, rising to $8.8B next year.
Top analysts covering Zimmer Biomet Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ZBH.
#1
Mike Matson
Needham · Rank #204
Hold
No targeton ZBH
Overall win rate
31%
+ Follow
#2
David Turkaly
JMP Securities · Rank #276
Buy
$105.00+9.7% to target
Overall win rate
31%
+ Follow
#3
Joanne Wuensch
Citigroup
Hold
$93.00-2.9% to target
Coverage
—
+ Follow
#4
Ryan Zimmerman
BTIG
Hold
No targeton ZBH
Coverage
—
+ Follow
#5
Matt Miksic
Barclays
Sell
$94.00-1.8% to target
Coverage
—
+ Follow
ZBH stock forecast FAQ
What is ZBH's average 12-month price target?+
The 15 analysts with a live target average $98.19 for Zimmer Biomet Holdings Inc over the next 12 months, ranging from a $112.00 high to a $86.00 low.
Is ZBH stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 19 analyst ratings, 6 are Buy or Strong Buy, 11 are Hold, and 2 are Sell or Strong Sell.
What are the highest and lowest price targets for ZBH?+
The Street-high target is $112.00, and the Street-low is $86.00 (UBS). The average of all 15 active targets is $98.19.
How many Wall Street analysts cover ZBH?+
19 analysts have an active rating on Zimmer Biomet Holdings Inc, and 15 firms carry a live 12-month price target.
Who is the most accurate analyst covering ZBH?+
Among analysts who currently cover ZBH, Mike Matson of Needham has the strongest overall Quantellect track record (Rank #204). Their current call is Hold.
What is Zimmer Biomet Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $1.88 per share (range $1.85 – $1.93) across 22 analysts. Full-year EPS is projected at $8.48, rising to $9.00 the following year.
How much revenue is Zimmer Biomet Holdings Inc expected to report next quarter?+
Consensus revenue is $2.0B (range $2.0B – $2.1B). Full-year revenue is projected at $8.5B, growing to $8.8B next year.
Have analysts been upgrading or downgrading ZBH lately?+
As of Jul, 6 of 19 firms rate ZBH a Buy (11 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ZBH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
BMO Capital
